

Novel stem cell treatment may hold promise for type 1 diabetes

By Serena Gordon, HealthDay

Updated 1/13/2012 4:05 PM

Recommend

84

1



A new type of stem cell treatment for people with type 1 diabetes appears to help re-educate rogue immune system cells, which allows cells in the pancreas to start producing insulin again.

The treatment, which combines a patient's immune system cells with stem cells from a donor's cord blood, even worked in people with long-standing diabetes who were believed to have no insulin-producing ability.

Although the treatment didn't wean anyone off insulin completely, average blood sugar levels dropped significantly, which would reduce the risk of long-term complications.

Paul Sancya, AP

The average daily dose of insulin dropped almost 39 percent after 12 weeks for the group with some beta cell function and 25 percent in those with no beta cell function.

Sponsored Links

LifeLock Ultimate™

Worried about credit card data breach? Protect yourself w/ LifeLock Ultimate LifeLock.com

Heart Attack Triggers

These 4 things are the deadliest heart attack triggers. Read this list www.newsmax.com

Map Your Flood Risk

Find Floodplan Maps, Facts, FAQs, Your Flood Risk Profile and More! www.floodsmart.gov

Buy a link here

But he's also "reasonably cautious," he said. "The follow-up is long, up to 40 weeks, but it's not long enough to declare victory against diabetes yet," said Inverardi.

Also, he noted that the study involved only 15 Chinese people, and that type 1 diabetes is a bit different in that population. He said he'd like to see larger studies with a more diverse population, followed for a longer time.

Results of the study were published online Jan. 9 in the journal *BMC Medicine*.

Type 1 diabetes, an autoimmune disease, occurs when the body's immune system cells mistakenly attack the insulin-producing (beta) cells in the pancreas. Because their beta cells don't produce enough or any insulin, people with type 1 diabetes have to replace the lost insulin through injections to survive.


Stopping that autoimmune attack appears to be crucial to any treatment that hopes to cure or reverse type 1 diabetes.

Zhao's team developed a completely new approach. They take blood from a patient and separate out the immune system cells (lymphocytes). They briefly expose those cells to stem cells from umbilical cord blood from an unrelated infant and return the lymphocytes alone to the patient's body. The researchers have dubbed this "Stem Cell Educator Therapy," because while exposed to the stem cells, the lymphocytes seem to relearn how they should behave.

The study participants, who were 15 to 41 years old, had had type 1 diabetes for an average of nine years. Six had some residual beta cell function and six did not. Both

Videos you may be interested in

[More videos](#)



Most Popular

Stories

- Floods cut part of I-10 as Debby storms...
- NBC: Matt Sandusky describes father's abuse
- FBI frees 79 teen prostitutes, nabs 104...
- Detroit to lay off 164 firefighters
- States consider raising fines for...

Videos

- Raw video: Coast Guard rescues stranded family and pets
- Raw Video: Debby soaks Florida's Gulf Coast
- Raw Video: 3 Missing After Okla. Train Wreck

Photos

- Editorial Cartoons
- Baby animals spring up at zoos
- Jerry Sandusky convicted

Most Popular E-mail Newsletter

Sign up to get:

Top viewed stories, photo galleries and community posts of the day

Most popular right now:
Floods cut part of I-10 as Debby storms over Fla.



Sign up for USA TODAY E-mail newsletters

groups were given stem cell educator therapy. The other three people served as the control group.

The researchers measured C-peptide, a protein fragment that's a byproduct of insulin production, and found that the educator therapy group had improved levels of C-peptide at 12 weeks. These levels continued to improve until 24 weeks, and remained stable through the follow-up at 40 weeks. There were no changes in C-peptide in the control group.

The average daily dose of insulin dropped almost 39 percent after 12 weeks for the group with some beta cell function and 25 percent in those with no beta cell function, suggesting that the group with no beta cell function now produced insulin.

"That means if you stop the autoimmune reaction, you may see beta cell regeneration, or there might be other precursor cells in the pancreas. If these data are confirmed, this is a very provocative and remarkable finding," Inverardi said.

The average hemoglobin A1C level dropped 1.06 percent for those with residual beta cell function and 1.68 percent for those without beta cell function. A1C levels measure average blood sugar levels over two to three months, and people with type 1 diabetes are advised to maintain A1C levels below 7 percent. A drop of 1 percent in A1C levels can reduce the risk of complications.

This was an initial clinical trial designed to test for safety. Zhao said that in future trials he hopes that with additional treatments people might get off insulin altogether.

But, even if that's not possible, the recovery of some beta cell function would be welcome news. "In the absence of complete remission, there are very sizable advantages to having some beta cell function," Inverardi noted.

Both experts said the treatment appears safe, with no risk of rejection. No significant side effects were reported during the trial, other than some arm soreness where blood was taken and returned.

For more information about [reprints & permissions](#), visit our [FAQ's](#). To report corrections and clarifications, contact Standards Editor [Brent Jones](#). For publication consideration in the newspaper, send comments to letters@usatoday.com. Include name, phone number, city and state for verification. To view our corrections, go to corrections.usatoday.com.

Posted 1/14/2012 6:00 AM | Updated 1/13/2012 4:05 PM



More from USATODAY

2 Alaska troopers shot, gunman found dead

USATODAY.com in News

Kids' cereal: still too sweet? Group updates 'worst' list

USATODAY.com - Your life

FDA approves new drug for erectile dysfunction

USATODAY.com - Your life

'Bachelorette' Emily picks her final four hometown guys

USATODAY.com in LifeLine Live

States consider raising fines for distracted driving

USATODAY.com in News

More from the web

ADHD Tips for the Summer Time

HealthCommunities

Flock of Birds Die After Flying Drunk

Zoobiquity

This Happens Right Before Your Heart Stops

Newsmax.com

Mom Billed for Blood Cleanup After Son Killed by a Drunk Driver

CafeMom

Cholesterol Meds Leave You Feeling Drained? Science Has the Answer!

Dr. Weil

[?]

USA TODAY is now using Facebook Comments on our stories and blog posts to provide an enhanced user experience. To post a comment, log into Facebook and then "Add" your comment. To report spam or abuse, click the "X" in the upper right corner of the comment box. To find out more, read the [FAQ](#) and [Conversation Guidelines](#).

16 comments

[Add a comment](#)



Cristy Holmes · Chattanooga, Tennessee

Type 1 diabetic since I was 2 years old. I'm now 35 years old, no kidney issues, no nerve damage, have all my fingers and toes and my eyes-though pretty nearsighted-can still see the obvious. No amount of letter-writing to the White House is going to produce a cure-big pharmaceuticals are making billions and trillions off of us, as are hospitals and doctors, shoe companies, sock companies, durable medical equipment supply companies, pharmacies, sugar-substitute companies, etc etc etc. And PLEASE don't get me started on Medtronic Minimed Corp, who boasted \$15.9 B-B-B-BILLION dollars in revenue for 2011, whilst they were scraping moths out of my wallet the whole time. Can we actually think that anyone would be stupid enough